Capstan Medical's Groundbreaking Achievement in Robotic Heart Surgery
Recently, Capstan Medical, based in Santa Cruz, California, announced a significant milestone: it has successfully completed its first U.S. robot-assisted transcatheter mitral valve replacement (TMVR) procedure. This groundbreaking surgical operation occurred on November 9 at The Christ Hospital in Cincinnati, Ohio, under the expert direction of Dr. Santiago Garcia, who leads the hospital's Structural Heart Program.
The procedure was part of an early feasibility study authorized by the U.S. Food and Drug Administration (FDA), which focuses on advancing treatment options for patients suffering from mitral valve disease, a condition that has traditionally posed challenges in terms of surgical intervention. In interviews following the operation, Dr. Garcia expressed optimism about this new avenue for treating structural heart diseases, emphatically stating, "This first U.S. procedure represents another significant step forward in the treatment of structural heart disease. I am pleased to report that the procedure was successful, and the patient was discharged home in stable condition."
Understanding Mitral Regurgitation and the Need for Innovation
Mitral regurgitation is a medical condition that arises when the mitral valve fails to close completely. This inadequacy allows blood to flow back through the heart, creating multiple long-term health issues for patients. Many individuals suffering from this condition are deemed too high-risk for conventional surgical options, while current catheter-based treatments do not cater to everyone. Thus, there exists a pressing need for alternative solutions that are both effective and minimally invasive.
Capstan Medical’s investigational TMVR technology is designed to fill this gap. Integrating a flexible, multi-axis catheter with robotic navigation and a new valve implant, the Capstan system offers increased precision during surgical procedures, which is crucial for navigating the heart’s complex anatomy. This innovative approach enables healthcare providers to execute the procedure while maintaining optimal control over catheter movement and valve deployment. Instead of manipulating multiple knobs on traditional catheter systems, physicians can now use a handheld controller that simplifies operations significantly, streamlining the entire process.
A Promising Future for Heart Valve Interventions
Maggie Nixon, CEO of Capstan Medical, expressed her enthusiasm regarding the future of heart valve interventions following this landmark operation. She stated, "This first U.S. case builds on our initial clinical experience and brings us another step closer to expanding treatment options to patients who need them most. The Capstan technology lays the foundation for what heart valve intervention should be: simple, reproducible, and low-stress. We couldn't be more excited for this milestone that makes that future a reality."
The recent milestone arrived on the heels of Capstan’s pioneering robotic-assisted mitral valve replacement procedures, which were successfully conducted in Chile in March 2025—events in which Dr. Garcia also participated. These advancements underscore Capstan Medical's commitment to revolutionizing the way heart valve surgeries are performed.
A New Era for Heart Valve Treatment
Founded in 2020, Capstan Medical aims to establish new standards for minimally invasive heart valve interventions. The company is actively developing a range of next-generation heart valve implants alongside a unique catheter-based robotic delivery platform. This innovation is intended to broaden treatment options for patients struggling with structural heart disease.
In conclusion, the successful completion of the first U.S. robotic-assisted TMVR procedure by Capstan Medical signals the dawn of a new era in heart valve treatment. As technology continues to evolve and improve, patients can look forward to more effective, less invasive surgical options that cater to a broader spectrum of medical needs. For more information about this promising technology and its implications for the future of heart health, visit
Capstan Medical’s website.
Note: The Capstan Compass TMVR system is still investigational and has not yet received FDA approval for commercial use in the United States.